Kala Pharmaceuticals (KALA) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 7, 2020 7:00 AM EDT-- Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020, Demonstrating Statistically Significant Results for Primary and Key Secondary Endpoints --
-- EYSUVISTM NDA Resubmitted on April 30th; Potential Approval and Launch Before Year-End --
-- Raised $146.9 Million in Gross Proceeds from Sales of Common Stock in Early 2020 --
-- 1Q 2020 INVELTYS® Revenue of $1.1 Million --
-- Conference Call and Webcast at 8:00 a.m. ET
WATERTOWN, Mass.--(BUSINESS WIRE)--
Kala... More
